Company Introduction

Otsuka Beijing Research Institute (OBRI) was established in 2003 as a research-based enterprise wholly owned by Otsuka Pharmaceutical Co., Ltd. of Japan, one of the world's leading comprehensive broad-based pharmaceutical companies, with a history of more than 80 years. Since its foundation, the primary focus of Otsuka Pharmaceutical’s research has been on the discovery and development of products such as new therapeutic drugs, healthcare products, health foods, medical and diagnostic devices and reagents, and Otsuka has produced and marketed these products along with the relevant services.

Thanks to the insightful cooperation between China’s State Food and Drug Administration (SFDA) and Otsuka Pharmaceutical, at the time under the leadership of Masahito Otsuka and Akihiko Otsuka, China Otsuka Pharmaceutical Co., Ltd. was successfully established in Tianjin in 1981 as the first joint venture between China and a Japanese company. Since its establishment, China Otsuka Pharmaceutical has actively contributed to the reform and opening of China’s medical and pharmaceutical industries. Otsuka has invested heavily in China, while at the same time introducing to China some modern business models and the current good manufacturing practices (cGMP) for medical products. As a result, Otsuka has earned a respected reputation and wide recognition throughout China’s medical and pharmaceutical fields.

For more than 20 years, Otsuka has continuously increased its investment in China, establishing about 30 companies (including joint ventures) in locations such as Guangdong, Sichuan, Shanghai, and Tianjin. Otsuka’s high profitability, sizeable investment, and wide range of operations in China have made it a leading name in Chinese business.

The Chinese economy continues to grow at a rapid pace, and Beijing is an important business and cultural center as well as the nation’s political capital. The city of Beijing is also making great advances in medical and pharmaceutical fields, and it is here that Otsuka established OBRI with an eye on future development. The mission of OBRI is 1.Import adaptable Otsuka’ medical products to China, and 2.Make contributions to Otsuka global clinical developments.OBRI’s operations include conducting clinical trials and registering promising new drugs with new indications in China, and all of these operations are conducted in full compliance with China’s laws and regulations as well as with internationally accepted ethical principles.

OBRI’s activities are expected to further expand Otsuka’s presence in China’s medical and pharmaceutical fields, reflecting the company’s motto of “Otsuka – people creating new products for better health worldwide.”

Home About Us Business Production Join Us Contact Us Otsuka       Otsuka Beijing Research Institute